Paul H. Berg

1.7k total citations · 1 hit paper
30 papers, 1.1k citations indexed

About

Paul H. Berg is a scholar working on Psychiatry and Mental health, Cardiology and Cardiovascular Medicine and Pharmacology. According to data from OpenAlex, Paul H. Berg has authored 30 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Psychiatry and Mental health, 8 papers in Cardiology and Cardiovascular Medicine and 6 papers in Pharmacology. Recurrent topics in Paul H. Berg's work include Schizophrenia research and treatment (7 papers), Bipolar Disorder and Treatment (4 papers) and Cardiac electrophysiology and arrhythmias (3 papers). Paul H. Berg is often cited by papers focused on Schizophrenia research and treatment (7 papers), Bipolar Disorder and Treatment (4 papers) and Cardiac electrophysiology and arrhythmias (3 papers). Paul H. Berg collaborates with scholars based in United States, United Kingdom and Germany. Paul H. Berg's co-authors include Alan Breier, Charles M. Beasley, Matthew J. Sheetz, Patrizia Cavazzoni, John M. Kane, Ira D. Glick, Erin Doty, Kevin L. Duffin, Philippe Zaoui and Julia B. Lewis and has published in prestigious journals such as JAMA, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Paul H. Berg

29 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation

2023 112 citations Stephen J. Nicholls, Steven E. Nissen et al. JAMA profile →

Peers

Countries citing papers authored by Paul H. Berg

Since Specialization

Citations

This map shows the geographic impact of Paul H. Berg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul H. Berg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul H. Berg more than expected).

Fields of papers citing papers by Paul H. Berg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul H. Berg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul H. Berg. The network helps show where Paul H. Berg may publish in the future.

Co-authorship network of co-authors of Paul H. Berg

This figure shows the co-authorship network connecting the top 25 collaborators of Paul H. Berg. A scholar is included among the top collaborators of Paul H. Berg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul H. Berg. Paul H. Berg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation breakdown → 2023 ·JAMA ·Stephen J. Nicholls, Steven E. Nissen, Cynthia Griggs Fleming, Shweta Urva, Jeffrey G. Suico, Paul H. Berg, Helle Linnebjerg, Giacomo Ruotolo, P. Kellie Turner, Laura F. Michael	112
2	Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials 2019 ·The Journal of Headache and Pain ·Robert E. Shapiro, Helen Hochstetler, Ellen B. Dennehy, Rashna Khanna, Erin Doty, Paul H. Berg, Amaal J. Starling	66
3	Targeting the hepcidin–ferroportin pathway in anaemia of chronic kidney disease 2019 ·British Journal of Clinical Pharmacology ·Matthew J. Sheetz, (unknown), Sophie Callies, Paul H. Berg, Juliet McColm, Thomas Marbury, Brian S. Decker, (unknown), Stephanie M.E. Truhlar, Robert J. Benschop, Donmienne Leung, Jolene Kay Berg, Derrick R. Witcher	57
4	Anti–TGF-β1 Antibody Therapy in Patients with Diabetic Nephropathy 2016 ·Journal of the American Society of Nephrology ·James R. Voelker, Paul H. Berg, Matthew J. Sheetz, Kevin L. Duffin, Tong Shen, Brian A. Moser, Tom Greene, Samuel S. Blumenthal, Ivan Rychlík, Yoram Yagil, Philippe Zaoui, Julia B. Lewis	213
5	Comparison of Treatment-Emergent Extrapyramidal Symptoms in Patients With Bipolar Mania or Schizophrenia During Olanzapine Clinical Trials 2006 ·The Journal of Clinical Psychiatry ·Patrizia Cavazzoni, Paul H. Berg, Ludmila Kryzhanovskaya, Susan D. Briggs, (unknown), Mauricio Tohen, John M. Kane	31
6	Olanzapine Versus Ziprasidone: Results of a 28-Week Double-Blind Study in Patients With Schizophrenia 2005 ·American Journal of Psychiatry ·Alan Breier, Paul H. Berg, Jogin H. Thakore, Dieter Naber, Wagner F. Gattaz, Patrizia Cavazzoni, Daniel Walker, (unknown), John M. Kane	122
7	Central Pain and Complex Motoric Symptoms after Gosarelin Therapy of Prostate Cancer 2004 ·The Scientific World JOURNAL ·Gernot Ernst, Adrian Gericke, Paul H. Berg	1
8	An Integrated Analysis of Acute Treatment-Emergent Extrapyramidal Syndrome in Patients With Schizophrenia During Olanzapine Clinical Trials 2003 ·The Journal of Clinical Psychiatry ·Christopher Carlson, Patrizia Cavazzoni, Paul H. Berg, (unknown), Charles M. Beasley, John M. Kane	47
9	Time to study discontinuation, relapse, and compliance with atypical or conventional antipsychotics in schizophrenia and related disorders 2002 ·International Clinical Psychopharmacology ·Ira D. Glick, Paul H. Berg	42
10	Analysis of the QTc Interval During Olanzapine Treatment of Patients With Schizophrenia and Related Psychosis 2001 ·The Journal of Clinical Psychiatry ·(unknown), Charles M. Beasley, Mary Anne Dellva, Paul H. Berg, Starr L. Grundy	81
11	Conservation Genetics of Freshwater Mussels: Comments on Mulvey et al. 2000 ·Conservation Biology ·David J. Berg, Paul H. Berg	11
12	Cardiac safety profile of olanzapine based on preclinical and clinical ECG data 2000 ·Schizophrenia Research ·(unknown), Mary Anne Dellva, Paul H. Berg, Starr L. Grundy, Charles M. Beasley	2
13	Conservation Genetics of Freshwater Mussels: Comments on Mulvey et al. 2000 ·Conservation Biology ·David J. Berg, Paul H. Berg	8
14	Effective resolution of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia with olanzapine 2000 ·European Neuropsychopharmacology ·Bruce J. Kinon, Bruce R. Basson, Angela Hill, Paul H. Berg	8
15	Olanzapineversushaloperidol in the treatment of schizoaffective disorder 1999 ·The British Journal of Psychiatry ·Pierre V. Trân, Gary D. Tollefson, T.M. Sanger, Yili Lu, Paul H. Berg, Charles M. Beasley	54
16	The psychosis of schizophrenia: prevalence, response to atypical antipsychotics, and prediction of outcome 1999 ·Biological Psychiatry ·Alan Breier, Paul H. Berg	54
17	Cardiac safety profile of olanzapine based on preclinical and clinical ECG data 1999 ·European Neuropsychopharmacology ·(unknown), Charles M. Beasley, Paul H. Berg	2
18	Quality Improvement in the Diagnosis and Treatment of Heart Failure by Participating Indiana and Kentucky Hospitals 1998 ·Evaluation & the Health Professions ·Glyn G. Caldwell, Paul H. Berg, (unknown), (unknown)	1
19	A pharmacodynamic model for the action of the antibiotic imipenem onPseudomonas aeruginosa populationsin vitro 1996 ·Bulletin of Mathematical Biology ·Paul H. Berg, Eberhard O. Voit, Roger L. White	12
20	A meta-analytical approach examining the potential relationship between talc exposure and ovarian cancer. 1996 ·PubMed ·(unknown), Paul H. Berg	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact